BUROSUMAB

Notice summary

The subject of the contract is the supply of the drug: burosumab 20mg injection solution and burosumab 30 mg injection solution with the active substance burosumab, known as Crysvita, for pediatric patients with X-linked hypophosphatemic rickets, meeting all the criteria listed below: 1) with documented high serum concentration of FGF-23 2) with genetically confirmed mutation in the PHEX gene 3) persistence of low hypophosphatemia despite long-term substitution with maximum t…